Company: SION
Filing Date: 2025-02-03
Form Type: S-1/A
Source: 0001193125-25-018825
Chunk: 142

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-02-03
Form: S-1/A
Chunk 142
---
 |      |                     | 1,144 |     |      |   | 1,051 |     |        |    93 |
| Total general and administrative expenses              |      | $                   | 9,388 |     |      | $ | 7,002 |     | $      | 2,386 |

General and administrative expenses increased by $2.4 million to $9.4 million for the nine months ended September 30, 2024, from $7.0 million for the nine months ended September 30, 2023. The increase in general and administrative expenses was primarily due to:

| • |     | $1.2 million increase in personnel-related (including stock-based compensation) primarily due to an increase in 
 stock-based compensation; and                                                                                   |

| • |     | $1.1 million increase in fees related to increased use of consultants and professional service organizations. |

Interest Income Interest income increased by $3.9 million to $6.1 million for the nine months ended September 30, 2024, from $2.2 million for the nine months ended September 30, 2023, primarily driven by an increased investment in debt securities due to the proceeds received from the issuance of our Series C preferred stock (the “Series C Financing”) and the amortization of discounts on our investment activity. Other Income Other income increased by $0.4 million to $0.5 million for the nine months ended September 30, 2024, from $0.1 million for the nine months ended September 30, 2023, driven by sublease income in connection with our subleasing agreement. Comparison of the Years Ended December 31, 2023 and 2022 The following table summarizes our results of operations (in thousands):

|                            | 2023 | Year Ended December 31, |         |   | 2022 |   |         |   |     | Change |        |   |
|:---------------------------|:-----|:------------------------|--------:|:--|:-----|:--|--------:|:--|:----|:-------|-------:|:--|
| Operating expenses:        |      |                         |         |   |      |   |         |   |     |        |        |   |
| Research and development   |      | $                       |  40,626 |   |      | $ |  34,605 |   |     | $